846
Participants
Start Date
May 31, 2019
Primary Completion Date
June 8, 2020
Study Completion Date
June 8, 2020
Lasmiditan
Administered orally
Placebo
Administered orally
Tominaga Hospital, Osaka
Sakura Clinic Internal Medicine Neurology, Toyama
Takanoko Hospital, Matsuyama
Ikeda Neurosurgical Clinic, Kasuga-shi
Jinnouchi Neurosurgery Clinic, Kasuga-shi
SUBARU Health Insurance Society Ota Memorial Hospital, Ota-shi
Nakamura Memorial Hospital, Sapporo
Kohnan Hospital, Kobe
Nishinomiya Municipal Central Hospital, Nishinomiya
Yamaguchi Clinic, Nishinomiya-shi
Fujitsu Clinic, Kawasaki
Sendai Headache and Neurology Clinic, Sendai
Okayama City General Medical Center Okayama City Hospital, Okayama
Chibune General Hospital, Osaka
Takase internal medicine clinic, Toyonaka-shi
Osoegawa Neurology Clinic, Saga
Saitama Medical University Hospital, Iruma-Gun
Saitama Neuropsychiatric Institute, Saitama
Saino Clinic, Tokorozawa
Dokkyo Medical University Hospital, Shimotsuga-Gun
Niwa Family Clinic, Chofu-shi
Sanno Clinic Shinagawa, Minato-ku
USUDA CLINIC for internal medicine, Setagaya-ku
Tokyo Headache Clinic, Shibuya-ku
Fukuuchi Pain Clinic, Shinjuku-ku
Nagaseki Headache Clinic, Kai-Shi
Doi Clinic Internal Medicine Neurology, Hiroshima
Tanaka neurosurgical clinic, Kagoshima
Umenotsuji Clinic, Kochi
Kumamoto City Hospital, Kumamoto
Tatsuoka Neurology Clinic, Kyoto
Ishikawa Clinic, Kyoto
Osaka Saiseikai Nakatsu Hospital, Osaka
Japanese Red Cross Shizuoka Hospital, Shizuoka
Eli Lilly and Company
INDUSTRY